Scientific Advisory Board
Dr. Toni Pérez
Chairman, Clinical Advisory Board
José Miguel Lizcano, PhD
Chairman, Scientific Advisory Board
Dr. Pere Gascón
Dr. Jordi Rodón
Miguel F. Segura, PhD
Dra. Soledad Gallego
Dra. Ana Oaknin
After working in several hospitals, she currently occupies the position of "Head of Gynecologic Cancer Program at Vall d'Hebron Institute of Oncology" (VHIO). Her professional career is mainly based on clinical research, being the principal investigator of numerous Phase I, II and III clinical studies, both national and international. She is a member of groups such as SEOM, GEICO, ESMO, GCIG, ASCO, GOG and NCI.
Antoni Martinez-Tobed, PhD
He worked for 27 years at the research center of Almirall, SA, as head of the pharmacokinetics and metabolism department, director of preclinical development and preclinical scientific director.
Antoni has a comprehensive knowledge of preclinical drug development, including bioanalysis, pharmacokinetics, metabolism, toxicology and clinical pharmacology, gained through over 35 years of experience in pharmaceutical companies and CROs.
He has a wide experience in assessment of preclinical and clinical pharmacology dossiers in development phases, and contributed to marketing approval of several new drugs in Europe, USA and Japan.
Jordi Espadaler, PhD
Research Advisor and co-Founder
Jordi obtained a BSc/MSc degree in biochemistry from the Autonomous University of Barcelona and also a PhD degree (Doctorate Extraordinary Award) from the same University. During his doctorate, Dr. Espadaler collaborated actively with Prof. Andrej Săli, a world-recognized expert in structural biology, and did several stays in his laboratory, both at the Rockefeller University (New York) and the University of California San Francisco.
In 2006 he joined AB-Biotics SA when the company had just two employees and helped it to grow from a small start-up to a publicly traded company with around 40 employees.
Jordi has published 10 articles in peer-reviewed journals and 3 patents (two of them are international patents), and is also a visiting professor since 2008 at the Master of Bioengineering of the Institut Químic de Sarrià (Ramon Llull University, Barcelona).
In 2009 Jordi cofounded Ability Pharmaceuticals, SL to become its Vice-President, Drug Discovery in September 2009.
NewsAbility Pharma sponsors the 37th National Meeting of the Spanish Society of Pharmacology + info
NewsAbility Pharmaceuticals launches a new updated website with a fresh design + info
NewsAbility Pharmaceuticals Announces FDA-Orphan Drug Designation for ABTL0812 in Pancreatic Cancer + info
NewsAbility Pharmaceuticals Initiates Phase 2 Combination Trial with ABTL0812 as First Line Therapy in Patients with Endometrial or Squamous Lung Cancer Patients + info
NewsAbility Pharmaceuticals Enters into a Licensing Agreement with SciClone Pharmaceuticals for the Novel Anticancer Agent ABTL0812 for the China Market. + info
NewsAbility Pharmaceuticals Receives Positive Opinion from EMA for Orphan Drug Status of ABTL0812 in Pediatric Cancer Neuroblastoma. + info
NewsAbility Pharmaceuticals to Present at the 7th Annual European Life Sciences CEO Forum in Zurich, March 4-5, 2014. + info
NewsABILITY PHARMACEUTICALS Initiates Clinical Trial with its Dual mTORC1/C2 Inhibitor ABTL0812 in Patients with Lung and Pancreatic Cancer + info
NewsAbility Pharmaceuticals to Present at the 6th Annual European Life Sciences CEO Forum in Zurich, March 5-6, 2013. + info